SPONSOR
Fondazione Ricerca Traslazionale
Total Trials
2
Recruiting
2
Phases
Phase 2
Fondazione Ricerca Traslazionale is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including NSCLC, Stage III NSCLC.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fondazione Ricerca Traslazionale
How many clinical trials has Fondazione Ricerca Traslazionale sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Fondazione Ricerca Traslazionale, of which 2 are actively recruiting participants. These trials cover conditions including NSCLC, Stage III NSCLC. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fondazione Ricerca Traslazionale research focus on?
Fondazione Ricerca Traslazionale clinical trials span NSCLC, Stage III NSCLC. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fondazione Ricerca Traslazionale clinical trial?
To participate in a Fondazione Ricerca Traslazionale trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fondazione Ricerca Traslazionale trials with current recruitment status updated daily.
Clinical Trials by Fondazione Ricerca Traslazionale
NCT07264673 Phase 2
Recruiting
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
NSCLC
NCT07264647 Phase 2
Recruiting
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Stage III NSCLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology